Genetic testing

PINNACLE FERTILITY PARTNERS WITH LABCORP TO ENHANCE GENETIC TESTING SERVICES

Retrieved on: 
Tuesday, March 5, 2024
Fertility, Health, Patient, Hope, Labcorp, Genetic testing, Partnership, Nursing

"Labcorp is uniquely positioned to support our services, making it easier for our clinics to optimize patient care."

Key Points: 
  • "Labcorp is uniquely positioned to support our services, making it easier for our clinics to optimize patient care."
  • Labcorp brings more than 50 years of experience and a focus on innovation in women's health and reproductive genetics to this partnership, enhancing the scope and quality of genetic testing services available to Pinnacle Fertility's patients.
  • "We are excited about our collaboration with Labcorp, which aligns with our commitment to offer advanced and personalized fertility solutions to our patients," said Beth Zoneraich, CEO at Pinnacle Fertility.
  • Pinnacle Fertility remains committed to a patient-centric approach, and the partnership with Labcorp reinforces this commitment by providing clear and actionable genetic information to individuals and couples navigating their fertility journey.

Avalon Saves Clients Millions, Sees Record Growth in 2023

Retrieved on: 
Tuesday, February 27, 2024
Chronic kidney disease, Insight, CKD, Organization, Patient, Policy, Genetic testing, Utilization management, Disease, Diagnosis, NCQA, Science, National Committee, HITRUST, Quality assurance, Medical device

TAMPA, Fla., Feb. 27, 2024 /PRNewswire/ -- Avalon Healthcare Solutions, the world's first Lab Insights company, enjoyed record-setting growth in 2023 while helping its health insurer clients save money, improve operations, and ensure the highest quality care for their members. That year, Avalon clients realized approximately 10% to 20% savings on their outpatient lab spending across lines of business. Approximately 25% of those savings benefit member spending and member out-of-pocket costs.

Key Points: 
  • TAMPA, Fla., Feb. 27, 2024 /PRNewswire/ -- Avalon Healthcare Solutions , the world's first Lab Insights company, enjoyed record-setting growth in 2023 while helping its health insurer clients save money, improve operations, and ensure the highest quality care for their members.
  • That year, Avalon clients realized approximately 10% to 20% savings on their outpatient lab spending across lines of business.
  • Due to this emphasis, Avalon experienced record growth in 2023.
  • Also, in 2023, Avalon launched Precision Genetic Testing Management (PGTM), the next evolution of its genetic test management solution.

GENETIC TESTING CAN SUPPORT THE FUTURE OF YOUR FAMILY

Retrieved on: 
Tuesday, February 27, 2024
Genetic disorder, Parent, Genetic testing, SLC13A5, Grunt, Digital technology, Patient, Family, Diagnosis, Agriculture, Seizure

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ --

Key Points: 
  • It can provide you with essential health information that could improve medical outcomes as well as unlock preventative steps for your family when they get genetic testing as well.
  • Toward the end of his hospital stay in early July, genetic testing results suggested that Rowan may have a rare genetic disorder called SLC13A5 citrate transporter deficiency, but it wasn't until October when his parent's own genetic testing from Invitae helped reach a definitive diagnosis for Rowan.
  • Michael Black, Vice Chair of the Board at TESS Research Foundation and father of Rowan shares his son's medical journey, the importance of genetic testing, and how the results from genetic testing specifically benefited his family.
  • His advocacy for genetic testing and awareness of rare disorders is driven by his son Rowan's battle with SLC13A5 Epilepsy.

Advocating for Equitable Cancer Care: A Call to Establish Comprehensive Survivorship Programming and Enhance Genetic Testing Discussions

Retrieved on: 
Thursday, February 22, 2024
Bias, Neoplasm, Cancer, Roger Hawkins (drummer), Somatic, HERC, ACS, Health, World Cancer Day, NCCN, Equity, Organization, Patient, Genetic testing, Biology, Community, Health equity, Estate (law), Pharmaceutical industry

PLYMOUTH MEETING, Pa. and WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. The new measures were put forth by a multi-disciplinary working group of experts in community oncology and agreed to by the original Elevating Cancer Equity working group members who drafted the original HERC. This expansion is part of ongoing efforts to address the impact of structural and interpersonal racism as a cause of disparities in cancer outcomes in the United States. The HERC was created by the Elevating Cancer Equity collaboration of the National Comprehensive Cancer Network® (NCCN®), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF).

Key Points: 
  • The HERC was created by the Elevating Cancer Equity collaboration of the National Comprehensive Cancer Network® (NCCN®), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF).
  • The two added measurements are:
    Establish comprehensive survivorship programming, including a process for continuity of care when a patient is due for discharge/transfer of care.
  • "These proactive measures are fundamental for promoting equitable healthcare and addressing the disparities that are far too prevalent in cancer care."
  • Visit NCCN.org/policy for more on NCCN's work to improve and facilitate quality, effective, equitable, and accessible cancer care so all patients can live better lives.

Auditory Insight Explains Hearing Loss Gene Therapy for Children

Retrieved on: 
Wednesday, February 21, 2024
Hearing, Deafness, Hearing loss, Hope, Human, Kool-Aid, Transgene, Therapy, Genetic testing, Patient, Optimism, Clinical trial, Ageing, Research, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 21, 2024 /PRNewswire/ -- Auditory Insight, a leading consultancy for the hearing healthcare industry, analyzes preliminary results for gene therapy clinical trials addressing deafness and hearing loss in its Q1 2024 Research Note.

Key Points: 
  • NEW HAVEN, Conn., Feb. 21, 2024 /PRNewswire/ -- Auditory Insight , a leading consultancy for the hearing healthcare industry, analyzes preliminary results for gene therapy clinical trials addressing deafness and hearing loss in its Q1 2024 Research Note.
  • In three sets of investigational clinical trials around the globe, gene therapy has transformed the hearing of children with a form of deafness from mutations in a gene called otoferlin.
  • She has advised gene therapy companies on surgeon, audiologist, and patient needs for gene therapy and genetic testing.
  • The trials also matter because they advance the learnings of scientists developing gene therapy for other forms of genetic hearing loss.

Unlocking the Secrets to Longevity: Live Beyond the Norms - A Global Online Summit Featuring Leading Health Experts

Retrieved on: 
Wednesday, February 21, 2024
Online, Secrecy, Multimedia, Diet, Ageing, Life, B cell, Health, Genetic testing, FREE, Research

The summit aims to address the growing shift in the research and medical communities towards understanding longevity.

Key Points: 
  • The summit aims to address the growing shift in the research and medical communities towards understanding longevity.
  • But why live longer if you don't have health, vitality, and a youthful mindset?
  • Ben Greenfield, offering a blueprint to a healthier life and unlocking key pillars for health and longevity.
  • To register for Uncovering the Secrets to Longevity: Live Beyond the Norms and access these transformative insights, visit https://secretstolongevity.byhealthmeans.com/?idev_id=33732 .

Synthpop unveils new possibilities for AI at the biggest DME gathering in the industry - MedTrade 2024

Retrieved on: 
Tuesday, February 20, 2024
Multimedia, API, HME, Innovation system, Itamar Medical, ResMed, Genetic testing, Health, DME, Electronic health record, Workflow

DALLAS, Feb. 20, 2024 /PRNewswire/ -- Synthpop will debut its cutting-edge AI solutions at MedTrade, the largest HME and DME gathering in the industry, March 26-28 2024.

Key Points: 
  • DALLAS, Feb. 20, 2024 /PRNewswire/ -- Synthpop will debut its cutting-edge AI solutions at MedTrade, the largest HME and DME gathering in the industry, March 26-28 2024.
  • Synthpop places an emphasis on connecting with other professionals at MedTrade to discuss advancements in AI that improve patient care while reducing administrative and clinical burnout.
  • *
    Synthpop has experienced early success as a healthcare startup, with customers in HME/DME, Sleep Medicine, Wound Care, and Genetic Testing.
  • "This trade show is a testament to our commitment to revolutionizing the DME industry with our innovative AI solutions .

AI (and other) Companies: Quietly Changing Your Terms of Service Could Be Unfair or Deceptive

Retrieved on: 
Friday, February 16, 2024
Division, FTC, Bureau, Crystal Celeste Grant, AI, Genetic testing, Policy, Hooked on Phonics, Consumer, Medical device

And there is perhaps no data refinery as large-capacity and as data-hungry as AI.

Key Points: 
  • And there is perhaps no data refinery as large-capacity and as data-hungry as AI.
  • But many of these companies also have privacy and data security policies in place to protect users’ information.
  • And to avoid backlash from users who are concerned about their privacy, companies may try to make these changes surreptitiously.
  • The company did that without notifying consumers who had previously shared personal data or obtaining their consent, said the FTC.

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

Retrieved on: 
Thursday, February 15, 2024
Cancer, OBGYN, Medicine, Education, MYGN, FACMG, Dillard University, Boston Market, Risk, Health, Myriad Genetics, FACOG, Genetics, Risk assessment, Associate, Genetic testing, Biology, Tufts Medical Center, Nursing

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately.
  • Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad.
  • “We’re thrilled to welcome Dallas to the Myriad team.
  • She is a passionate women’s health leader and patient advocate who is committed to advancing diversity, equity and inclusion in clinical care and education,” said Melissa Gonzales, president of women’s health, Myriad Genetics.